Insider buying last 90 days
No open-market insider purchases were filed for BMY in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every BMY insider filing, plotted on the chart in Gekko.Open BMY in Gekko
NYSE: BMY
Bristol-Myers Squibb (BMY) Stock Analysis & Forecast
$63.06+0.22 (+0.4%)
Close on Sep 18, 2026. Page updated Sep 19, 9:15 pm ET.
Gekko Brief
AI summaryBristol-Myers Squibb closes at $63.06, up 0.4%, sitting between its 50-day average of $64.01 and 200-day average of $58.86. The GekkoIndex reads 67.1, placing BMY in the Accumulation zone, and the stock trades 41.4% below Gekko Fair Value of $107.66. Over the past year the stock has returned 36.6%, though the most recent month shows a 6.7% decline against a three-month gain of 16.8%.
This week's coverage centers on Sotyktu, with two-year data showing durable responses in psoriatic arthritis as competition in that space increases. Coverage also includes comparisons of BMY against sector peers including AbbVie and argenex, along with confirmation that third-quarter 2026 results will be released on 29 October, with a conference call scheduled for 8:00 a.m. ET that day. Broader market commentary references easing oil prices and lower Treasury yields following the Federal Reserve's recent rate hike as context for renewed attention on healthcare names.
Looking ahead to the next 20 trading days, the earnings date of 29 October falls 39 days out, beyond that window. Seasonality over this calendar stretch has averaged a 0.4% decline across 5 years, with gains in only 2 of those years. Analyst coverage spans 20 firms, with 8 at buy, 11 at hold, and 1 at sell, and a consensus target of $66.71 implying 5.8% upside from current levels. No insider, Congress, or unusual options activity appears in the respective 90-day and 30-day windows.
Written by AI and checked automatically against the figures on this page. Generated Sep 20, 2026 from the data above.
Price vs fair value
Close $63.06200-day averageGekko Fair Value $107.66
Key stats
- Market cap
- $128.8B
- P/E ratio
- 13.8
- Forward P/E
- 9.7
- EPS, TTM
- $4.54
- Revenue, TTM
- $49.19B
- Profit margin
- 18.9%
- Dividend yield
- 3.95%
- Beta
- 0.23
- Volume
- 36.83M avg 8.94M
- 1-year return
- +36.6%
- Typical daily move
- ±2.1%
- Typical 20-day move
- ±4.3%
- 50-day average
- $64.01
- 200-day average
- $58.86
- Next earnings
- Oct 29 before open
- Shares outstanding
- 2.04B
Bristol-Myers Squibb swing-trade checklist
Bristol-Myers Squibb scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed1 headwind
- Trendmixed
Averages disagree
Close $63.06 sits between the 50-day ($64.01) and 200-day ($58.86) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
67.1, Accumulation
Reading 67.1 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
41.4% below
Price is 41.4% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 39 days
Next report Oct 29, 2026, 39 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−0.4% on average
From this point in the calendar, the next 20 trading days averaged −0.4% over 5 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Bristol-Myers Squibb stock chart and price history
Bristol-Myers Squibb closed at $63.06 on Sep 18, 2026, +36.6% over the past year, inside a 52-week range of $42.52 to $68.64.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −6.7%
- 3 months
- +16.8%
- 6 months
- +8.5%
- 1 year
- +36.6%
The full BMY chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open BMY in Gekko
Follow Bristol-Myers Squibb through every session
Put BMY on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track BMY in GekkoFree for 7 days. No credit card required.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a biopharmaceutical company engaged in researching, developing, and manufacturing medicines that it sells around the world. Its work covers areas such as blood disorders, cancer, heart and immune conditions, fibrosis, neurological disease, and infectious illness including COVID-19. Among its widely used products are Revlimid for multiple myeloma, Eliquis for stroke prevention and blood clot conditions, and Opdivo for a range of cancers, alongside therapies like Orencia for arthritis and Breyanzi, a cell-based immunotherapy for lymphoma.
Its broader lineup includes Pomalyst, Sprycel, Yervoy, Abraxane, Reblozyl, Empliciti, Zeposia, Inrebic, and Onureg, covering conditions from leukemia and melanoma to multiple sclerosis and anemia. These medicines reach patients through wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government bodies, forming a broad commercial network rather than direct sales to individual consumers.
The company traces back to 1887 and was previously called Bristol-Myers Company. It is headquartered in New York, New York, and its shares are listed on the NYSE under the ticker BMY.
- Listed
- NYSE
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- bms.com
Bristol-Myers Squibb GekkoIndex: the smart money zone
Bristol-Myers Squibb’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 67.1, in the Accumulation zone, up 4.4 points over five sessions.
67.1Accumulation
Up 4.4 points over five sessions.
Reading for Sep 18, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 35 | −0.1% | −2.0% | ||
| Accumulation (current zone) | 202 | +0.4% | +2.1% | ||
| Neutral | 392 | +0.4% | +1.2% | ||
| Distribution | 32 | −1.5% | −0.6% | ||
| Selling | 1 | Too few readings yet | |||
Average BMY share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.3% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the BMY price, zone by zone.Track BMY in Gekko
Is Bristol-Myers Squibb stock overvalued? Gekko Fair Value
Bristol-Myers Squibb trades 41.4% below Gekko Fair Value of $107.66, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Bristol-Myers Squibb shares are worth, recalculated every trading day.
$107.66
Gekko Fair Value, Sep 19, 2026
41.4% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open BMY in Gekko
Bristol-Myers Squibb insider and Congress trading
No open-market insider purchases were filed for Bristol-Myers Squibb, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in BMY were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for BMY, plotted on the chart in Gekko.Open BMY in Gekko
Buybacks
Bristol-Myers Squibb has been buying back its own shares.
- Bought back, quarter ended Mar 31, 2026
- $98.00M
- As a share of market cap
- 0.08%
From company filings.
Hedge funds and billionaires quarter ended Mar 31
2of the funds Gekko tracks hold BMY.
1added0opened1trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
Bristol-Myers Squibb earnings: next date and track record
Bristol-Myers Squibb reports on Oct 29, 2026, before the open (39 days away), and beat the EPS estimate in 7 of its last 8 reports.
Next earnings report
Oct 29, 2026
Expected before the open, 39 days away
- EPS estimate
- $1.68
- Revenue estimate
- $12.62B
7 of 8reports beat the EPS estimate
±4.2%average move across the report
5 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Jul 30, 2026 AI summary
- What they said
- Bristol-Myers Squibb reported a strong Q2 2026 with total revenue up 5% year-over-year (~$13B) driven by a 14% increase in the growth portfolio (now ~60% of revenue). Key growth products cited include Reblozyl, Breyanzi, Camzyos, Opdualag, Qvantig (now annualizing >$1B), and Eliquis (demand-driven growth of 21%). Management increased full-year 2026 revenue and adjusted EPS guidance and emphasized disciplined investment, a broad late-stage pipeline, and business development discipline. They highlighted positive clinical updates (e.g., SUCCESSOR-2 mezigdomide data) and multiple upcoming readouts (admilparant in IPF/PPF, Sotyktu in SLE, moponetug tau data next year). Management discussed milvexian (event-driven AFib study) and Cobenfy (ADEPT) enrollment timing—both moving into 2027 readout windows due to slower-than-expected event accrual or deliberate quality-focused enrollment. Overall tone combined commercial execution confidence with cautious explanations for several trial timing shifts. They reiterated focus on operational improvements in clinical trial conduct and R&D prioritization.
- Guidance
- Management stated they are increasing full-year 2026 revenue and adjusted diluted EPS guidance based on strong first-half momentum and confidence in the second half. No specific numeric guidance figures were disclosed in the transcript.
- Risks flagged
- Mentioned risks and challenges include slower-than-expected event accrual in several event-driven trials (milvexian AFib, ADEPT-1/Cobenfy), enrollment pace and quality-driven delays in ADEPT-2/ADEPT-4, generic competition impact on legacy portfolio (full generic availability of Revlimid in U.S.), potential step-down in Eliquis revenue after 2026 and patent expirations (Eliquis LOE April 2028; Europe mid-Q4), and general clinical trial execution risks (study design, statistical assumptions, comparator performance).
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Jul 30, 2026 | $2.04 est $1.59 | $12.97B est $11.74B | +3.5% |
| Apr 30, 2026 | $1.58 est $1.44 | $11.49B est $10.93B | +1.1% |
| Feb 5, 2026 | $1.26 est $1.63 | $12.50B est $12.28B | +7.6% |
| Oct 30, 2025 | $1.63 est $1.52 | $12.22B est $11.85B | +8.1% |
| Jul 31, 2025 | $1.46 est $1.09 | $12.27B est $11.44B | −3.8% |
| Apr 24, 2025 | $1.80 est $1.49 | $11.20B est $10.70B | −1.3% |
| Feb 6, 2025 | $1.67 est $1.47 | $12.34B est $11.57B | −4.8% |
| Oct 31, 2024 | $1.80 est $1.49 | $11.89B est $11.26B | +3.2% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Bristol-Myers Squibb stock forecast and analyst price targets
Analysts’ average 12-month price target for Bristol-Myers Squibb is $66.71, +5.8% from the last close, from 20 firms rating the stock in the last 90 days.
$66.71consensus 12-month target, +5.8% from the last close
Now $63.06Avg $66.71
Low $40High $82
Each firm’s latest rating in the last 90 days: 20 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 16 | Piper Sandler | $82 | +30.0% |
| Sep 14 | RBC Capital | $64 | +1.5% |
| Sep 10 | HSBC | $65 | +3.1% |
| Sep 9 | Scotiabank | $60 | −4.9% |
| Sep 9 | BMO Capital | $60 | −4.9% |
+2.1%average 20-day move after past Accumulation readings
−0.4%average move over the next 20 trading days in the last 5 years
±2.1%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Bristol-Myers Squibb seasonality: the next 20 trading days
Over the next 20 trading days from Sep 19, Bristol-Myers Squibb averaged −0.4% across the last 5 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −0.6% | 1 of 5 |
| Next 10 trading days | +0.9% | 3 of 5 |
| Next 15 trading days | −1.5% | 1 of 5 |
| Next 20 trading days | −0.4% | 2 of 5 |
| Next 30 trading days | +0.7% | 3 of 5 |
For scale, BMY’s typical 20-trading-day move in either direction is about 4.3%.
Bristol-Myers Squibb market cap and key statistics
Bristol-Myers Squibb’s market cap is $128.8B, with a P/E ratio of 13.8 and revenue of $49.19B over the last twelve months.
Valuation
- Market cap
- $128.8B
- P/E ratio
- 13.8
- Forward P/E
- 9.7
- EPS, TTM
- $4.54
- Gekko Fair Value
- $107.66
Trading
- Volume
- 36.83M
- Avg volume, 20 days
- 8.94M
- 52-week high
- $68.64
- 52-week low
- $42.52
- Shares outstanding
- 2.04B
Financials
- Revenue, TTM
- $49.19B
- Profit margin
- 18.9%
- Return on equity
- 46.6%
- Quarterly earnings growth, YoY
- +153.1%
Risk and income
- Beta
- 0.23
- Typical daily move
- ±2.1%
- Typical 20-day move
- ±4.3%
- Dividend yield
- 3.95%
Bristol-Myers Squibb stock news this week
Coverage of Bristol-Myers Squibb this week reads positive: 10 positive, 7 neutral and 1 negative headlines.
- Can Sotyktu's Long-Term PsA Data Boost Bristol Myers' Prospects?Zacks Investment Research, Sep 18
- How Bristol-myers Squibb Company (BMY) Affects Rotational Strategy TimingStock Traders Daily, Sep 18
- AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?Yahoo Finance, Sep 18
- BMY vs. ARGX: Which Stock Is the Better Value Option?Zacks Investment Research, Sep 18
- Bristol Myers Squibb to Report Results for Third Quarter 2026 on October 29, 2026BioSpace, Sep 18
- What Is Driving Attention to Bristol Myers Squibb (NYSE:BMY)?Kalkine Media, Sep 18
Bristol-Myers Squibb peers
Bristol-Myers Squibb’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Accumulation | 15.7% above |
| JNJJohnson & Johnson | Neutral | 2.7% below |
| ABBVAbbVie | Neutral | 22.6% above |
| MRKMerck | Neutral | 7.3% below |
| AZNAstraZeneca | Neutral | 41.0% below |
| PFEPfizer | Neutral | 9.8% below |
A peer links to its own page where one exists.
Bristol-Myers Squibb stock FAQ
What is Bristol-Myers Squibb’s market cap?
Bristol-Myers Squibb’s market cap is $128.8B at the Sep 18, 2026 close of $63.06, with 2.04B shares outstanding. The shares trade on a P/E ratio of 13.8.
What is the Bristol-Myers Squibb stock forecast?
The consensus analyst 12-month price target for Bristol-Myers Squibb is $66.71, +5.8% from the last close. Of the 20 firms that rated the stock in the last 90 days, 8 rate it a buy, 11 a hold and 1 a sell. Gekko doesn’t publish price predictions of its own.
Is Bristol-Myers Squibb stock overvalued or undervalued?
On Gekko’s estimate Bristol-Myers Squibb is undervalued: the Sep 18, 2026 close of $63.06 is 41.4% below Gekko Fair Value of $107.66. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Bristol-Myers Squibb report earnings next?
Bristol-Myers Squibb is expected to report on Oct 29, 2026, before the market opens (39 days away). Analysts expect earnings of $1.68 per share on revenue of $12.62B. Bristol-Myers Squibb beat the earnings estimate in 7 of its last 8 reports, moving 4.2% on average across the report.
What is Bristol-Myers Squibb’s 52-week high and low?
Bristol-Myers Squibb’s 52-week high is $68.64 and its 52-week low is $42.52; it closed at $63.06 on Sep 18, 2026, +36.6% over the past year.
Is Bristol-Myers Squibb stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (gekkoindex, fair value and earnings risk), 1 as mixed (trend) and 1 as a headwind (seasonality). The checklist is a description of current data, not a recommendation.
How this page works
Prices and signals update after every US market close; the GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Bristol-Myers Squibb the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,349 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.